TS-1+ Oxaliplatin+ Bevacizumab therapy in consideration of OPTIMOX design for metastatic colorectal cancer

ABSTRACT: Interventions: TS-1+ Oxaliplatin+ Bevacizumab/TS-1+ Bevacizumab Primary outcome(s): DDC ; Duration of disease control Study Design: Single arm Non-randomized

DISEASE(S): Metastatic Colorectal Cancer

PROVIDER: 2629292 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR